| Canaloplasty may be alternative to trabeculectomy
| Non-penetrating procedure found safe, effective, with similar side effects, no hypotony
| | Ophthalmology Times | Non-penetrating Schlemm's canaloplasty may be a safe and effective alternative to standard trabeculectomy. A retrospective comparison study found no statistically significant differences in IOP reduction or medication usage at up to 1 year of follow-up. Adjunctive procedures and complications were similar in the two groups of patients, although no long-term hypotony was seen in the canaloplasty group. |
| | Brimonidine/timolol controls IOP in clinical setting
| Fixed-combination solution may lead to improved patient adherence to therapy as well
| | Ophthalmology Times | | Brimonidine 0.2%/timolol 0.5% fixed-combination ophthalmic solution effectively lowers and controls IOP and is likely to be associated with increased patient adherence to therapy and decreased unwanted side effects such as ocular irritation, according to one ophthalmologist. |
| | Glaucoma minishunt under scleral flap demonstrates long-term efficacy and safety
| Retrospective study documents long-term efficacy, safety of procedure used alone or with phaco
| | Ophthalmology Times | | A retrospective study analyzed outcomes of 345 consecutive eyes with the proprietary glaucoma minishunt (Ex-PRESS, Optonol) implanted, including 114 eyes having combined cataract surgery. During a mean follow-up of about 2 years, the implant provided effective IOP control whether used alone or in a combination procedure and was associated with few complications. |
| | Glaucoma: Hyperemia a common cause for medication changes
| Choosing appropriate initial therapy could lead to lower costs, increased adherence
| | Ophthalmology Times | | Hyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens. |
| | Glaucoma: Trabecular micro-bypass device aids IOP reduction in prospective study
| Stent procedure is additive to pressure-lowering effect of cataract surgery, according to surgeon
| | Ophthalmology Times | | Implantation of a trabecular micro-bypass (iStent, Glaukos Corp.) in patients with open-angle glaucoma who are undergoing cataract surgery represents an alternative surgical approach that can provide clinically significant reductions in IOP and use of ocular hypotensive medications. |
|
| World Sight Day set for Oct. 8
| | Ophthalmology Times E-News | | Three hundred events in more than 50 countries will mark this year's World Sight Day, Oct. 8. |
| | Aton expands programs for preservative-free timolol
| | Ophthalmology Times E-News | | Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States. |
| | NicOx and Pfizer sign agreement for PF-03187207
| | Ophthalmology Times E-News | | NicOx has signed an agreement with Pfizer to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open-angle glaucoma and ocular hypertension, according to a prepared statement. |
| | |
| 
Practice Tools
